Chimeric Therapeutics Limited
CHMMF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $2 | $31 | $8 | $34 |
| - Cash | $6 | $3 | $2 | $18 |
| + Debt | $0 | $4 | $0 | $0 |
| Enterprise Value | -$4 | $32 | $6 | $16 |
| Revenue | $4 | $0 | $5 | $3 |
| % Growth | – | -100% | 72.2% | – |
| Gross Profit | $3 | -$0 | $5 | $2 |
| % Margin | 78.7% | – | 100% | 63.7% |
| EBITDA | -$9 | -$11 | -$24 | -$14 |
| % Margin | -228.7% | – | -533% | -520.5% |
| Net Income | -$10 | -$13 | -$26 | -$16 |
| % Margin | -262.8% | – | -566% | -607.5% |
| EPS Diluted | -0.008 | -0.018 | -0.059 | -0.044 |
| % Growth | 57.2% | 69.4% | -33.3% | – |
| Operating Cash Flow | -$7 | -$8 | -$16 | -$13 |
| Capital Expenditures | $0 | $0 | -$0 | -$1 |
| Free Cash Flow | -$7 | -$8 | -$16 | -$14 |